期刊
APPLIED BIOLOGICAL CHEMISTRY
卷 64, 期 1, 页码 -出版社
SPRINGER SINGAPORE PTE LTD
DOI: 10.1186/s13765-021-00659-6
关键词
BSA-Au nanozymes; Anticancer nanodrug; Jurkat; Anti-apoptotic genes; Acute T-type lymphoblastic leukemia
The study indicates that BSA-Au nanozymes can be a potential nanodrug for treating T-type lymphoblastic leukemia by reducing the expression of anti-apoptotic genes, enhancing the effects of common anticancer drugs, and improving patient survival rates.
In this paper, the bovine serum albumin protected gold nanozymes (BSA-Au nanozymes) were utilized as a novel nanodrug for treatment of acute T-type lymphoblastic leukemia (Jurkat) by production of excessive ROS and effect on the expression of anti-apoptotic genes. The effect of BSA-Au nanozymes on the Bcl-2 expression and survivin in the Jurkat cell line was checked. The results showed that the expression of anti-apoptotic genes was significantly reduced after treatment of the Jurkat cell line with the BSA-Au nanozymes (p-value of 0.001) as the potential nanodrug while their expression in the normal PBMC was not affected by the nanodrug. Moreover, the cytotoxic effect of the developed nanodrug on the Jurkat cell line was evaluated which illustrated that survival rate in the studied cell line reaches its minimum value (100% lethality, 0.0% survival) after treatment for 48 h. The IC50 for the nanodrug was calculated at 0.05 mM of the developed nanodrug. Overall, the BSA-Au nanozymes can be used as the nanodrug for treatment of T-type lymphoblastic leukemia via reducing the expression of anti-apoptotic genes, increasing the effect of common anticancer drugs such as Adriamycin and ara-C, and consequently increasing the survival of patients with leukemia.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据